TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00966264
Drug: LNG-IUS
Approvals — FDA: no, EMA: no, PMDA: no
Description: LNG-IUS releasing 25 microg of levonorgestrel
Study: NCT01090011
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2992 medium dose plus high dose level of cetuximab
Study: NCT01090011
Drug: BIBW 2992
Approvals — FDA: no, EMA: no, PMDA: no
Description: BIBW 2992 medium dose monotherapy, upon progression, cetuximab high dose is added
Study: NCT04396847
Drug: Placebo oral tablet
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo Oral Tablet (BID)
Study: NCT04597970
Drug: cTACE-HAIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: transarterial chemoembolization (TACE) plus Hepatic Arterial Infusion Chemotherapy (HAIC) with oxaliplatin and raltitrexed for Barcelona stage C hepatocellular carcinoma (HCC)
Study: NCT03455205
Drug: shenqifuzheng
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500ml shenqifuzheng daily（at day 1-7and day22-28）through intravenous infusion.
Study: NCT00671710
Drug: Aminolevulinic Acid
Normalized name: Aminolevulinic Acid
DrugBank: Aminolevulinic acid (DB00855)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Escalating doses (10mg/kg, 20mg/kg, 30mg/kg) of Aminolevulinic Acid administered orally 3 hours prior to surgery to enhance visualization of malignant brain tumor.
Study: NCT06119347
Drug: AntiVEGF
Approvals — FDA: no, EMA: no, PMDA: no
Description: anti-vascular endothelial growth factor monoclonal antibody drug includes bevacizumab;
Study: NCT03533777
Drug: To keep open (TKO) infusion of 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: After placement of the peripheral intravenous catheter, an infusion of 0.9% normal saline will be connected to the catheter and infused at a rate of 20 milliliters per hour to keep open (TKO) for future use by preventing blood clot development within the catheter.
Study: NCT02660762
Drug: Intrathecal Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: induction therapy I：12.5 mg IT d15 induction therapy II：12.5 mg IT d1, 8, 15, 22
Study: NCT02660762
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: induction therapy II:650 mg/m2 IV d1, 15, 29 consolidation therapy(Cycle 3)：650 mg/m2 IV，d29
Study: NCT01612247
Drug: Cyclophosphamide and Methotrexate and Aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cyclophosphamide 50 mg PO daily x 28 days, cycles 1-4 Methotrexate 2.5 mg PO twice daily, days 1 and 2 each week x 4 weeks, cycles 1-4 ASA: 325 mg PO daily x 28 days, cycles 3 and 4 Treatment will be given for a total of 4 cycles.
Study: NCT02034162
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo will be administered as a single-dose chewable tablet. For children 1 year to \<36 months of age, the tablet will be placed in a teaspoon and bottled water will be poured into the remaining volume of the teaspoon. The tablet will then be allowed to absorb all water (absorption time has been observed to take less than 1 minute) to become a soft semi-solid mass without any hard particles. This semi-solid form can then be easily ingested by the child.
Study: NCT02660762
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intensification therapy:3 g/m2 intravenously given on days 1, 8, and 22 Maintenance therapy:20 mg/m2 orally or intravenously once a week for a total of 2.5 years.
Study: NCT01240538
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given PO
Study: NCT01289132
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo-matching tablets, orally, once daily for up to 12 weeks.
Study: NCT03436303
Drug: CEE 0.625 mg/MP 100mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: CEE 0.625 mg daily/MP 100mg daily for the last 12 days of every 28 days for two years
Study: NCT00008281
Drug: FOLFOX regimen
Normalized name: Anacin Aspirin Regimen Pill
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00008281
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00008281
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02209844
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02479997
Drug: Radioisotope
Normalized name: Radioisotope
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nuclear medicine uses radiation to provide diagnostic information about the functioning of a person's specific organs, or to treat them. Diagnostic procedures using radioisotopes are now routine.
Study: NCT01229774
Drug: Etoricoxib
Normalized name: etoricoxib
DrugBank: Etoricoxib (DB01628)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Arcoxia 90 mg once a day in the evening day -1 and 0 and once a day in the morning days 1-7 plus on tablett of placebo every evening
Study: NCT01229774
Drug: Diclofenac
Normalized name: Diclofenac
DrugBank: Diclofenac (DB00586)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Voltaren Resinat 75mg once a day on day -1 and 0 in the evening; twice a day (in the morning and in the evening) days 1-7
Study: NCT00608725
Drug: Intrinsic Heart Rate
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 0.04 mg/kg IV in divided doses Propranolol 0.2 mg/kg IV in divided doses
Study: NCT01508637
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: capsule, identical in appearance to terazosin capsule, by mouth, 30 minutes prior to exposure initiation
Study: NCT00582725
Drug: R-CHOP+GM-CSF
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: addition of GM-CSF
Study: NCT02828397
Drug: REGN2222
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02503826
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: low dose
Study: NCT02503826
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: moderate dose
Study: NCT02503826
Drug: Sufentanil
Normalized name: Sufentanil
DrugBank: Sufentanil (DB00708)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: high dose
Study: NCT04058470
Drug: R-CHOP Protocol
Normalized name: pantolactone, (R)-
Approvals — FDA: no, EMA: no, PMDA: no
Description: After toripalimab plus rituximab treatment, R-CHOP regimen will be administered every 3 weeks in combination with R-CHOP up to 6 cycles.
Study: NCT03617068
Drug: Cocos Nucifera Whole
Normalized name: COCOS NUCIFERA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Applying the Cocos Nucifera Whole cream for 2 weeks, on both of arms. We evaluated the score of hand dermatitis using Hand Eczema Score Index ( HECSI), transepidermal water loss (TEWL), and Skin capacitance
Study: NCT03617068
Drug: Cocos Nucifera Whole
Normalized name: COCOS NUCIFERA WHOLE
Approvals — FDA: no, EMA: no, PMDA: no
Description: For dermatopharmacokinetic evaluation using tape/ skin stripping
Study: NCT01350232
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: All subjects will receive cyclophosphamide at a dose of 60 mg/kg at approximately 72 and 96 hours after the lymphocyte infusion
Study: NCT02825186
Drug: Loteprendol etabonate 0.5%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid eye drops used after strabismus surgery.
Study: NCT04429282
Drug: ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients were randomly divided into three groups in radio 1:1:1 received respectively IV placebo, ibuprofen 400 mg or ibuprofen 800 mg. The first dose of study drugs was administered intravenously at the time of wound closure and then every 6 hours within 48 hours after the operation.
Study: NCT04429282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01625936
Drug: CRLX101 (Cerulean)
Normalized name: SAMBUCUS NIGRA SUBSP. CERULEA FRUIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRLX101 is an innovative tumor-targeting nanopharmaceutical.
Study: NCT01667926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04853901
Drug: Standard of care_1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hydroxycoloroquine 400mg twice on day 1 then 200mg tab twice 2-10 days
Study: NCT04853901
Drug: Standard of care_2
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylprednisolone 1-2mg/kg for 5-7 days
Study: NCT00840996
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: perioperative placebo IV saline infusion of 2 mg/kg/h with maximum of 200 mg/h starting at induction of anesthesia and continuing until discharge from the PACU or a maximum of 8 hours
Study: NCT03518528
Drug: Estradiol 2 MG
Normalized name: estradiol 2 MG
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Vaginal estradiol (Provames, Sanofi) 4mg per day from day 3 to first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks
Study: NCT03518528
Drug: Estradiol 100 µg
Normalized name: estradiol 100 MG
DrugBank: Estradiol acetate (DB13952)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: transdermal estradiol (Vivelledot, Novartis) 100 µg on day 3, then 200 µg day 7 and every 4 days, until first pregnancy test. If pregnancy test is positive, treatment is to continue until 8 weeks.
Study: NCT02034019
Drug: Punctum Plug
Normalized name: Hippeastrum puniceum whole extract
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01352143
Drug: Recombinant activated factor VII
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma will be spiked in vitro with recombinant activated factor VII to assess increases in thrombin generation with and without the drug
Study: NCT00944229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4 capsules of placebo every 24 hours
Study: NCT00162617
Drug: Red blood cell transfusion
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01296009
Drug: Traditional Chinese medicine(Zhuyun Recipe)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The patients undergoing IVF-ET take orally traditional Chinese medicine(Zhuyun Recipe) for ten days.
Study: NCT02383992
Drug: 3% H2O2 solution
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02383992
Drug: 0.9% normal saline
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00867100
Drug: 700 mg IV
Approvals — FDA: no, EMA: no, PMDA: no
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
Study: NCT00867100
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single SC or IV dose in healthy subjects (Part A) and subjects with moderate to severe psoriasis (Part B).
Study: NCT02484378
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline
Study: NCT02906020
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pharmaceutical form: capsule Route of administration: oral
Study: NCT02701062
Drug: Anticoagulation Therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Anticoagulation Therapy- Standard of Care at the discretion of the Investigator.
Study: NCT01973140
Drug: Hypertonic saline infusion
Approvals — FDA: no, EMA: no, PMDA: no
Description: A week after the first intervention(tolvaptan), the subjects will undergo a hypertonic saline infusion for 6 hours. Blood and urine samples will be collected at specified time points until 4hour hours after the infusion.
Study: NCT01598103
Drug: SAF312
Approvals — FDA: no, EMA: no, PMDA: no
Description: One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
Study: NCT01598103
Drug: Placebo to SAF312
Approvals — FDA: no, EMA: no, PMDA: no
Description: One week of treatment in a BID (two times a day) regimen (hard gelatin capsules for oral use)
Study: NCT04360122
Drug: Levamisole and Isoprinosine
Normalized name: Levamisole
DrugBank: Levamisole (DB00848)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Levamisole (150 mg/day for two days per week for 2 months and Isoprinosine (1 g 3 times per day daily) for two months
Study: NCT04434248
Drug: Standard of Care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard of Care will be prescribed in accordance with the recommended treatment regimens presented in the Russian guidelines for the prevention, diagnosis and treatment of COVID-19 according to the decision of the Investigator.
Study: NCT00698282
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00216047
Drug: PTK787
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTK787 daily
Study: NCT02036437
Drug: Misotac® Sigma Pharmaceutical Industries
Approvals — FDA: no, EMA: no, PMDA: no
Description: The solution will be orally administrated every two hours (maximum 12 hours) until adequate uterine contractions obtained (3 per 10 minutes each lasting 40-60 seconds) and then stopped. The initial dose of 20 ml (20 ug) will be increased to 40 ml (40ug) after two doses if there are no contractions. The timing and strength of contractions will be assessed by abdominal palpation. If the contractions are inadequate, augmentation of the active phase of labor will be attempted by hourly-titrated oral misoprostol (20 ml) +/- amniotomy. If the uterine contractions are judged to be adequate, the next dose of misoprostol will be omitted.
Study: NCT02036437
Drug: Dinoprostone 3 mg
Normalized name: dinoprostone 3 MG
DrugBank: Dinoprostone (DB00917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Dinoprostone 3 mg (Dinoglandin® Alexandria Co. for Pharmaceuticals) will be inserted in the posterior vaginal fornix and repeated after six hours if contractions are inadequate (i.e. two doses maximum). If the contractions become inadequate, augmentation of the active phase of labor will be attempted by Syntocinon (oxytocin) infusion +/- amniotomy.
Study: NCT02579824
Drug: DS-3032b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: Escalation DS-3032b starting dose level 90 mg/day administered once daily by mouth on Days 1 - 21 of a 28 day cycle. For Dose Expansion maximum tolerated dose from Dose Escalation Phase.
Study: NCT01150045
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients receive celecoxib 400 mg administered by mouth, once daily.
Study: NCT01150045
Drug: leucovorin
Normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients receive 400 mg/m\^2 intravenous over two hours.
Study: NCT00884650
Drug: oral analgesic
Normalized name: Oral Analgesic Paste Maximum Strength
Approvals — FDA: no, EMA: no, PMDA: no
Description: per clinical standard of care
Study: NCT00884650
Drug: intravenous analgesic per pump
Normalized name: Analgesic Balm GRX
Approvals — FDA: no, EMA: no, PMDA: no
Description: per clinical standard of care
Study: NCT02054676
Drug: Medications.
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be given amoxicillin 500mg for every 8 hours or clindamycin 300mg for every 8 hours for 7 - 10 days after surgery.~Patients will be given Ibuprofen 600mg every 12 hours for pain relief following surgery at least for first three days as needed.~Patients will be given chlorhexidine 0,12% mouth rinse at least every 8 hours starting 24 hours after surgery for 14 days.
Study: NCT00435851
Drug: Thyrogen, thyroid hormone withdrawal, iode 131
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00543062
Drug: Inhaled placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Inhaled Staccato placebo (0 mg)
Study: NCT02791490
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral tablet, once daily at approximately the same time each day
Study: NCT00543062
Drug: Oral placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral placebo (identical to 400 mg moxifloxacin)
Study: NCT01620970
Drug: PF03446962
Approvals — FDA: no, EMA: no, PMDA: no
Description: PF-03446962 will be administered in 1hr intravenously at a dose of 10 mg/Kg on day 1, then every 2 weeks until the evidence of disease progression or onset of unacceptable toxicity.
Study: NCT00021047
Drug: capecitabine
Normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02075619
Drug: Amlodipine+Rosuvastatin
Normalized name: rosuvastatin and amlodipine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amlodipine 10mg will be supplied as white or off-white, emerald shaped tablet. Rosuvastatin 20mg will be supplied as pink round film coated tablet.
Study: NCT02075619
Drug: GSK3074477 FDC - 1
Normalized name: DYE FDC BLUE #1
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
Study: NCT02075619
Drug: GSK3074477 FDC - 2
Normalized name: DYE FDC BLUE #2
Approvals — FDA: no, EMA: no, PMDA: no
Description: GSK3074477 containing combination of 10mg amlodipine and 20mg rosuvastatin, will be supplied as white caplet shaped film coated tablet.
Study: NCT01923896
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: lactose powder
Study: NCT03069144
Drug: HAT1 topical solution
Approvals — FDA: no, EMA: no, PMDA: no
Description: HAT1 topical solution will be applied twice daily. The research team will provide instructions for the correct application of the treatment. If a lesion disappears, patients will continue applying the cream twice daily to the area. No additional creams, lotions or soaps other than provided test products will be allowed throughout the duration of the study.
Study: NCT00610909
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00620269
Drug: Induction or consolidation IP chemotherapy
Normalized name: Medicated Pad or Tape
Approvals — FDA: no, EMA: no, PMDA: no
Description: Irinotecan 65mg/m2 + Cisplatin 30mg/m2 IV on D1,D8 every 3 weeks X 3 cycles
Study: NCT00867737
Drug: Advair HFA MDI 115/21
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two puffs from MDI twice daily for 4 weeks
Study: NCT00867737
Drug: Symbicort 160/4.5 pMDI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Symbicort 160/4.5 pMDI~Two puffs from MDI twice daily for 4 weeks
Study: NCT00865852
Drug: GLUCOPHAGE® XR 750 mg tablets, single dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: B: Active comparator Subjects received Bristol-Myers Squibb Company formulated products under non-fasting conditions
Study: NCT04451811
Drug: OPL-002
Normalized name: ethanol
DrugBank: Ethanol (DB00898)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Spray dried dispersion and tablet formulation
Study: NCT01519778
Drug: TR701 FA
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 tablet 200 mg once daily
Study: NCT01006616
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to navarixin capsules
Study: NCT01006616
Drug: Rescue medication
Normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
Approvals — FDA: no, EMA: no, PMDA: no
Description: Short-acting β-agonist (SABA), anticholinergic, or a combination SABA/anticholinergic
Study: NCT03672175
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SAGE-217 matched placebo hard gelatin capsules.
Study: NCT01322009
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: After obtaining written parental consent, patients will be randomized by the use of a blind envelope system to one of the following: to receive probenecid (initial: 25 mg/kg/dose; maintenance: 10mg/kg/dose 4 x per day for 11 doses) and NAC (initial: 140mg/kg/dose; maintenance: 70mg/kg/dose 6 x per day for 17 doses) or the placebo via nasogastric (NG) or orogastric (OG) tube for 3 days. Placebo contents include equal volumes and dosing regimens of lactose powder (for opacity) suspended in Ora-Plus and normal saline.
Study: NCT00905034
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 200 mg/m\^2 by vein on days 1 and 15.
Study: NCT03251612
Drug: Based on sensitivity analysis
Normalized name: Fluorimax Sensitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: * 5FU, infusional~* Capecitabine~* Oxaliplatin (FOLFOX)~* Irinotecan (FOLFIRI)~* FOLFOXIRI (triplet)~* Bevacizumab~* Panitumumab~* Cetuximab~* Regorafenib~* Tas-102~* Ramucirumab~* Aflibercept~* Pembrolizumab~* Nivolumab~* Vinorelbine and capecitabine~* Sorafenib~* Gemcitabine and capecitabine~* Olaparib~* Epirubicin
Study: NCT03856047
Drug: NNC0174-0833
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will get one dose of NNC0174-0833 once weekly. The medicine is injected with a thin needle in a skin fold in the stomach, thigh or upper arm using NovoPen® 4. Participants will gradually increase the dose until they reach the target dose, and will continue on the this dose once weekly up to 26 weeks.
Study: NCT00927498
Drug: conventional chemotherapy (AraC + Daunorubicin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.
Study: NCT00927498
Drug: Mylotarg associated with conventional chemotherapy (AraC + Daunorubicin),
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin(DNR) induction : 60 mg/m2/day IV (30 min), Days 1,2,3 Daunorubicin (DNR)first consolidation : 60 mg/m2 day 1. Daunorubicin (DNR)second consolidation : 60 mg/m2 day 1 and day 2.~Cytarabine induction :200 mg/m2/day by continuous infusion, Days 1 to 7. Cytarabine (AraC)first and second consolidation: 1g/m2/12h days 1 to 4.~Mylotarg® (GO)induction : 3 mg/m2 IV (2 hours) Days 1, 4, 7. Mylotarg® (GO) First consolidation and Second Consolidation:3 mg/m2 day 1.
Study: NCT04211389
Drug: ARQ-151 0.3% cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-151 0.3% cream
Study: NCT04211389
Drug: ARQ-151 vehicle cream
Normalized name: Neisseria meningitidis group B strain NZ98/254 outer membrane vesicle
Approvals — FDA: no, EMA: no, PMDA: no
Description: ARQ-151 vehicle cream
Study: NCT00474929
Drug: RAD001
Approvals — FDA: no, EMA: no, PMDA: no
Description: Phase I: Dose level 0: RAD001 5mg every other day; Dose level 1: RAD001 5mg every day; Dose level 2: RAD001 5mg every day; Dose level 3: RAD001 10mg every day; Phase II: RAD001 5mg every day;
Study: NCT03938064
Drug: Prontogest 400 mg vaginal pessaries
Approvals — FDA: no, EMA: no, PMDA: no
Description: natural progesterone in the form of vaginal suppositories 400 mg
Study: NCT01348152
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Subjects will be randomized to 15 g/day of placebo. Dosage is granule. Subjects will ingest two 2.5 g doses of placebo three times daily for 34 consecutive days.
Study: NCT02280057
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 pills per day in six months; pills look like metformin pills